Paid Clinical Trials in Fairfield, CT
As of August 2026, 48 paid clinical trials are recruiting in Fairfield, Connecticut. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Fairfield offers studies at sites including Smilow Cancer Hospital Care Center-Fairfield for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Stage IV Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Fairfield
Trials by drug in Fairfield
Filter results
Newly added in Fairfield
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
48 clinical trials
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
ATEMPT 2.0: Adjuvant T-DM1 vs TH
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Top Research Study Locations in Fairfield
Researchers run research studies in Fairfield, CT at 12 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Smilow Cancer Hospital Care Center-Fairfield | Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma | 37 |
| Hartford Healthcare - Fairfield | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 3 |
| Smilow Cancer Hospital - Fairfield | Breast Cancer, Breast Neoplasms | 2 |
| Dermatology Physicians of Connecticut | Alopecia, Areata Alopecia, Hair Diseases | 1 |
| Fairfield Surgery Center | Lumbar Spinal Stenosis | 1 |
| Fairfield University | Vaping | 1 |
| Galderma Investigational | Prurigo Nodularis | 1 |
| Galderma Investigational | Atopic Dermatitis | 1 |
| Sacred Heart University | Acquired Brain Injury | 1 |
| Smilow Cancer Hospital Care Center | HER2-positive Metastatic Breast Cancer | 1 |
| Smilow Cancer Hospital Care Center - Fairfield | Metastatic Breast Cancer | 1 |
| Smilow Cancer Hospital Care center at Fairfield | Breast Cancer, HER2-positive Breast Cancer | 1 |
Active & Upcoming Studies in Fairfield (2026)
Recruiting trials in Fairfield grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (38 active studies)
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · Phase 3 · NRG Oncology
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study · Phase 2 · SWOG Cancer Research Network
Common conditions studied in Fairfield
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Breast Cancer (4 active studies)
- Stage IV Lung Cancer AJCC v8 (4 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Fairfield
- SWOG Cancer Research Network
- National Cancer Institute (NCI)
- NRG Oncology
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Fairfield?
There are approximately 48 recruiting clinical trials in Fairfield, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fairfield pay participants?
Most recruiting trials in Fairfield compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fairfield?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fairfield?
The most common conditions under active study in Fairfield include Anatomic Stage II Breast Cancer AJCC v8 (4), Breast Cancer (4), Stage IV Lung Cancer AJCC v8 (4), Recurrent Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fairfield?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fairfield on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fairfield?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fairfield?
Recruiting research sites in Fairfield include Smilow Cancer Hospital Care Center-Fairfield, Hartford Healthcare - Fairfield, Smilow Cancer Hospital - Fairfield, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fairfield right now?
The largest active categories in Fairfield are Cancer & tumors (38). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.